



FOR IMMEDIATE RELEASE

Contact:

Bill Edelman
CEO, TyRx Pharma, Inc.
Office: 732-246-8676
Direct: 732-964-1101
Cell: 617-759-5451
william@tyrxpharma.com

**TyRx Pharma, Inc., Announces the Appointment of
Robert M. (Bob) Mattioli as Vice President, Commercial Development**

Monmouth, NJ, (December 11, 2007) -- TyRx Pharma, Inc., a leader in the commercialization of implantable medical-pharmaceutical devices today announced that it has appointed Robert M. Mattioli as Vice President, Commercial Development. "Bob brings over 30 years experience in building commercial organizations to TyRx and we are excited to have him join our team," remarked William Edelman, President and CEO for TyRx. Mr. Edelman continued, "Bob's tremendous depth and experience will continue our strategy in the implantable medical-pharmaceutical device sector as TyRx moves from the development stage to a full commercial footing. Bob will begin immediately establish our commercial distribution channel with an aggressive recruitment of sales and marketing expertise in the electrophysiology sector."

Mr. Mattioli has more than 30 years of successful sales and marketing management experience in the cardiovascular device industry, focused on cardiac arrhythmia therapies. He has held key executive management positions at St. Jude Medical, Guidant, Biotronik Inc. and Cordis Corporation. Most recently, As Vice President, Global Sales for Cryocath Technologies Inc., Mr. Mattioli was the principal architect for the successful commercial global adoption of cryoablation technology for cardiac arrhythmia applications, growing revenue to \$40M within 4 years of its commercial launch.

Mr. Mattioli remarked, "TyRx is positioned to be an important leader in the emerging medical device sector whereby pharmaceutical therapies delivered by medical device systems expand the capabilities of both. I am excited to be once again engaged in building growing and sustainable revenue for an important emerging technology, building on my extensive experience in the explosive cardiac arrhythmia market."

This notice follows TyRx's October 19th announcement for the paper entitled, "Prevention of Experimental Capsular Contracture in Breast Implants by an Antimicrobial-Impregnated

Biodegradable Wrap” that was presented during the American Society for Plastic and Reconstructive Surgery (ASPRS) *Plastic Surgery 2007*, October, 28 2007 in Baltimore, MD.

On October 16th, 2006, TyRx Pharma, Inc., filed a Premarket Notification for AIGIS™ Rx (previously known as PIVIT™ CRM), an anti-infective innovative mesh pouch coated with TyRx’s proprietary bioresorbable polymer, containing the antimicrobial agents, rifampin and minocycline. AIGIS™ Rx is designed to enclose a pacemaker or ICD pulse generator when implanted in the body, and acts to provide protection from infection of a pulse generator following its surgical implantation. According to a recent study presented during the Heart Rhythm Society 2006 Scientific Sessions (Boston) the University of Pittsburgh Medical Center noted that the 2003 national incident of infection for pacemakers was estimated to be 5.82% and for ICDs 3.71%. Recent market research indicates that more than 500,000 pulse generators are implanted each year.

About TyRx Pharma, Inc.

TyRx Pharma, Inc., an ISO 9001:2000 and ISO 13485:2003 certified medical device manufacturer, commercializes combination medical products utilizing novel biomaterials technology licensed exclusively from Rutgers, The State University of New Jersey. Additionally, TyRx has exclusively licensed from Baylor College of Medicine and The University of Texas M. D. Anderson Cancer Center product patents and associated technologies to address the problem of postsurgical nosocomial infection. TyRx is deploying its capabilities across a broad range of combination products. The combination products sector (products incorporating both a drug & a device component) is expected to be the highest growth segment of the medical products industry and TyRx is positioned to be an innovative applications leader in the space. For more information, please visit www.tyrxpharma.com.

#####